[ad_1]
Medicine
Thursday, July 5, 2018
In intracytoplasmic sperm injection (ICSI), a sperm is injected directly into the cytoplasm of the oocyte with the help of a micropipette. / dpa
Barcelona – Men whose sperm undergoes fertility treatment with the ICSI (Intracytoplasmic Sperm Injection) microinjection technique have a significantly higher risk of prostate cancer, according to an badysis of 3 Swedish national registries. The reason for this is not ICSI, but male infertility, researchers from Lund University in Sweden pointed out at the annual congress of the European Society of Reproductive Medicine and of the University of Lund, Sweden. embryology (ESHRE) in Barcelona. ICSI can therefore be used as a predictor of prostate cancer.
The data come from the Swedish Register of Births, Cancer and Assisted Reproductive Quality of nearly 1.2 million fathers whose first child was born between 1994 and 2014 The Swedes were born. Of these, 3,211 men had prostate cancer. The researchers compared ICSI fathers to fathers who became fathers through routine IVF or natural control. In Sweden, ICSI is reserved for men who are also unable to help with IVF because of severely restricted semen production.
Infertile ICSI men had a significantly higher risk (47%) of developing prostate cancer than men in the control group. It was mostly early prostate tumors diagnosed before the age of 50 years. These "beginner" tumors occurred 3 times more frequently in men who used ICSI than in the control group. No increased risk, however, has been observed in the ICSI group for prostate cancer, which occurs later. Men in the IVF group did not have an increased risk of prostate cancer compared to the control group.
The increased risk of prostate cancer is certainly not due to ICSI treatment itself. Yahia Al-Jebari, Lund University
"The results show a high risk of early prostate cancer," said the authors of the ESHRE. They also pointed out that this form of cancer was "generally more aggressive". While prostate cancer is one of the most common cancers in men, early prostate cancer is quite rare. In the group studied, only one in 1000 daughters was diagnosed before the age of 50.
"The increased risk of prostate cancer is certainly not due to ICSI treatment," said a Swedish researcher, Yahia Al-Jebari. ICSI has no biological effect on humans. The researchers suspect that men already had a tumor at the time of ICSI and could benefit from screening.
An existing tumor could affect fertility anyway. In addition, a low rate of male bad hormone, testosterone or testosterone for the treatment of hypogonadism as possible factors of influence would be conceivable. However, early diagnosis of prostate cancer may also be a side effect of regular PSA screening, available for men who are undergoing testosterone supplementation.
Advertising
Source link
